Endocrinology · Medical Literature
CMS’ GLP-1 Bridge Demonstration
Abstract
This Viewpoint discusses the US Centers for Medicare & Medicaid Services’ (CMS) extension of the Medicare Glucagon-Like Peptide-1 (GLP-1) Bridge and outlines unanswered questions related to how the bridge will affect Medicare.
Clinical relevance
The Medicare GLP-1 Bridge addresses a long-standing statutory gap in Medicare coverage by providing the first-ever temporary pathway for Part D beneficiaries to access GLP-1 receptor agonists (semaglutide, tirzepatide, orforglipron) specifically for obesity management — a population previously excluded from standard Part D drug coverage. An estimated 3.8 million Part D enrollees are potentially eligible under the demonstration's clinical criteria, representing a substantial unmet need among the Medicare population with obesity. Clinicians must engage with this policy now because the demonstration runs only through December 31, 2027, the longer-term BALANCE Model has been delayed indefinitely, and no permanent legislative coverage mechanism exists — meaning patients face an abrupt coverage cliff requiring proactive counseling and planning.
Key findings
1. Program scope and timeline: The Medicare GLP-1 Bridge launched July 1, 2026, and was extended through December 31, 2027 (18 months total), after being originally designed as a 6-month stopgap; the extension was necessitated by the indefinite delay of the BALANCE Model after major Part D insurers declined to commit. 2. Eligible population: KFF analysis estimated approximately 3.8 million Part D enrollees met Bridge eligibility criteria in 2023; up to an estimated 20 million Medicare beneficiaries may meet broader clinical criteria for GLP-1 therapy for weight loss, but most are excluded from the Bridge due to existing Part D-covered indications (T2DM, OSA, MASH). 3. Cost-sharing structure: Beneficiaries pay a flat $50 monthly copayment; notably, this copayment does not count toward the Part D deductible, does not apply toward the out-of-pocket maximum ($2,100 in 2026; $2,400 in 2027), and Low-Income Subsidy (LIS/Extra Help) cost-sharing subsidies do not apply — creating a potential financial burden for low-income enrollees. 4. Drug pricing: Manufacturers have agreed to a negotiated net price of $245 per 30-day supply, with the difference between wholesale acquisition cost and this net price returned to CMS. 5. Projected program expenditure: At 10%–25% uptake among eligible beneficiaries, the Bridge is projected to cost Medicare an estimated $1.3 billion to $3.3 billion over its 18-month run. 6. Coverage exclusions and prescriber burden: Beneficiaries already receiving GLP-1 coverage through Part D for T2DM, cardiovascular risk reduction, moderate-to-severe OSA, or MASH are ineligible for the Bridge; prior authorization — submitted electronically or by fax — is required for each eligible beneficiary, with mandatory attestation of BMI ≥35 (or BMI ≥30 with a qualifying comorbidity such as HFpEF or uncontrolled hypertension) and concurrent lifestyle modification.
Practice implications
Endocrinologists and primary care physicians should proactively identify eligible patients — those with BMI ≥35, or BMI ≥30 with qualifying comorbidities (HFpEF, uncontrolled hypertension) who lack a Part D-covered GLP-1 indication — and submit prior authorization requests via the Bridge's centralized system (Humana/LI NET infrastructure) specifying weight-management diagnosis codes. Clinicians must counsel patients — particularly those on Low-Income Subsidy programs — that the flat $50 copay receives no cost-sharing assistance and does not count toward their annual out-of-pocket maximum, which may render the program unaffordable for some. Given the December 2027 coverage cliff, with no confirmed pathway to permanent Medicare coverage for obesity pharmacotherapy and the BALANCE Model indefinitely delayed, physicians should document clinical response and comorbidity burden longitudinally to support future coverage advocacy, and begin contingency planning for medication continuity well before the demonstration's expiration.
Evidence appraisal
Methodology critique
{"methodologyCritique":"This is a Viewpoint/opinion piece rather